Veritas In Silico Inc. (TYO:130A)

Japan flag Japan · Delayed Price · Currency is JPY
486.00
+11.00 (2.32%)
At close: Feb 16, 2026
Market Cap3.16B -38.3%
Revenue (ttm)91.14M -53.2%
Net Income-425.67M
EPS-65.62
Shares Out6.49M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume15,500
Average Volume370,720
Open476.00
Previous Close475.00
Day's Range476.00 - 492.00
52-Week Range428.00 - 942.00
Beta-0.89
RSI45.08
Earnings DateFeb 12, 2026

About Veritas In Silico

Veritas In Silico Inc. engages in the business of small molecule drug discovery and nucleic acid drug discovery targeting mRNA. The company has strategic partnership with Liverpool ChiroChem for the mRNA-targeted drug discovery and development. Veritas In Silico Inc. was incorporated in 2016 and is based in Shinagawa, Japan. [Read more]

Industry Surgical and Medical Instruments and Apparatus
Founded 2016
Country Japan
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 130A
Full Company Profile

Financial Performance

In 2025, Veritas In Silico's revenue was 91.14 million, a decrease of -53.18% compared to the previous year's 194.64 million. Losses were -425.67 million, 80.0% more than in 2024.

Financial Statements